Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse

Item

http://www.wikidata.org/entity/Q39452113

Q39452113

about

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients.Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment.

P2860

Q37613310-EB7E2EF0-FF7C-4D32-ABD0-56310E5FD242 Q45817286-B9BCC15D-C106-47F2-B37A-54BB53396FF6 Q48614611-64EE662D-ADA8-4E83-BDCE-14A5348C3D22 Q53090926-015EDF69-6D9D-45AE-AEAB-0FF64769891E Q53147059-E4624EE8-7C21-44C3-B85E-6D58F7582280

P2860

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse

Item

http://www.wikidata.org/entity/Q39452113

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse

@en

Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse

@nl

type

Item

label

Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse

@en

Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse

@nl

prefLabel

Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse

@en

Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse

@nl

P1476

Rituximab, cyclophosphamide-fr ...... y diagnosed, high-risk diffuse

@en

P2093

Andre Goy

http://www.w3.org/2001/XMLSchema#string

Andrew Pecora

http://www.w3.org/2001/XMLSchema#string

Anthony Mato

http://www.w3.org/2001/XMLSchema#string

Arun Singavi

http://www.w3.org/2001/XMLSchema#string

Christina Howlett

http://www.w3.org/2001/XMLSchema#string

David Panush

http://www.w3.org/2001/XMLSchema#string

Gabriella Gadaletta

http://www.w3.org/2001/XMLSchema#string

Harry Agress

http://www.w3.org/2001/XMLSchema#string

Kar Fai Chow

http://www.w3.org/2001/XMLSchema#string

Kathryn Waksmundzki

http://www.w3.org/2001/XMLSchema#string

P2860

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.

Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.

P304

2606-2612

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2013.783909

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23488604

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse

about

P2860

P2860

Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921